Previous reports showed that the prognostic impact of CHIP expression level was different depending on the organ of interest: cytoplasmic CHIP IHC expression was associated with shorter OS in colorectal carcinoma [28] and shorter cancer-specific survival in gallbladder cancer [29]; on the other hand, nuclear CHIP IHC expression was associated with longer cancer-specific survival in breast cancer [30], and cytoplasmic IHC expression was associated with longer OS in head and neck cancer [31]. This evidence concerns the gene STUB1 and colorectal carcinoma.